Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E5BW
|
|||
| Former ID |
DIB009553
|
|||
| Drug Name |
[131I]-Metuximab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 2 | [1] | |
| Company |
Elsevier
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Basigin (BSG) | Target Info | . | [2] |
| Pathway Interaction Database | Syndecan-1-mediated signaling events | |||
| Reactome | Degradation of the extracellular matrix | |||
| Basigin interactions | ||||
| Integrin cell surface interactions | ||||
| Pyruvate metabolism | ||||
| WikiPathways | The citric acid (TCA) cycle and respiratory electron transport | |||
| Integrin cell surface interactions | ||||
| Cell surface interactions at the vascular wall | ||||
| Matrix Metalloproteinases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00819650) A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection. U.S. National Institutes of Health. | |||
| REF 2 | Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):435-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.